A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer

Inclusion Criteria:

* Subjects who understand and sign the consent form for this study
* Males age ≥18 years
* Subjects diagnosed with metastatic hormone-sensitive prostate cancers (mHSPC) or metastatic castration-resistant prostate cancer (mCRPC)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Expected survival time of at least 24 months
* Adequate hematologic, renal, and liver function: WBC greater than 3.5 x 109/L; Absolute neutrophils count greater than 1.5 x 109/L; Platelet count greater than 80 x 109/L; Hemoglobin at least 90g/L; AST less than 2 x upper limit of normal (ULN); Creatinine less than 1.5 x ULN
* No obvious abnormalities in the electrocardiogram

Exclusion Criteria:

* Clinically significant cardiovascular disease: New York Heart Association (NYHA) class III or IV chronic congestive heart failure, coronary heart disease (myocardial infarction within 6 months); cardiac arrhythmia requiring anti-arrhythmic drug (beta-blocker or digoxin is allowed to be used); uncontrolled high blood pressure
* HIV infection
* Acute exacerbation of chronic hepatitis A or hepatitis B infection
* The subject has uncontrollable seizures required pharmacotherapy (such as steroids or antiepileptic drugs)
* The subject has a history of allogeneic organ transplants
* Subject with irregular hemorrhagic disease
* The subject receives dialysis treatment The subject has a history of other malignant tumor except subjects with curable basal cell carcinoma, superficial bladder tumor or other tumors has been cured over three years of study entry
* The subject has a history of gastrointestinal hemorrhage within 30 days of study entry
* The subject has an allergic history or is allergic to the drug in this study
* The subject has serious diseases of respiratory, nervous or mental system
* Subject with immune disease, auto-immune disease requires systemic ongoing immunosuppressive therapy
* The subject has problems with drug or alcohol abuse
* Major surgery within 4 weeks of enrollment
* Prior autologous bone marrow transplantation within 4 weeks of enrollment
* The subject has participated in any other therapeutic clinical trial with an experimental drug in the 4 weeks prior to this trial
* The subject has any other unsuitable or adverse condition to be determined by the investigator
* Any medical intervention or any circumstances that could compromise the safety and compliance of the trial subjects